Laurel B. Darragh, MD/PhD student in the department of immunology at University of Colorado Denver-Anschutz Medical Campus, and colleagues sought to assess the safety of hypofractionated SBRT with neoadjuvant single-dose durvalumab among 21 patients (median age, 61 years; 67% men; 66.7% heavy smokers) with HPV-unrelated head and neck squamous cell carcinoma.